Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 2 study titled A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects With Generalized Anxiety Disorder Who Have Had an Inadequate Response to Antidepressant Therapies. The study aims to assess the safety and efficacy of ABBV-932 when added to existing antidepressant therapies in adults with generalized anxiety disorder (GAD) who have not responded adequately to standard treatments.
The intervention being tested is ABBV-932, an investigational oral drug intended to enhance the effectiveness of antidepressant therapies in treating GAD. Participants will receive either ABBV-932 or a placebo alongside their current antidepressant regimen.
This study is interventional, randomized, and uses a parallel assignment model. It employs quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary purpose of the study is treatment-focused.
The study began on February 21, 2025, with the latest update submitted on August 28, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results.
For investors, this study could significantly impact AbbVie’s stock performance if ABBV-932 proves effective, potentially positioning the company as a leader in the GAD treatment market. The study’s outcome may also influence investor sentiment and competitive dynamics within the pharmaceutical industry.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.